Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc

Registered Charity 3104


Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.


ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

Cancer Drug Doesn't Work For Chronic Fatigue

Tuesday 11 June 2019


From ScienceNordic:



Cancer drug doesn’t work for chronic fatigue

Cancer drug rituximab has no effect on chronic fatigue syndrome (ME/CFS), according to a Norwegian study.

By: Ingrid P. Nuse, based on an article by Ingrid Spilde
June 10, 2019

“Now we can put this to rest,” says researcher Øystein Fluge.

He is referring to the idea that the cancer drug rituximab, which affects certain cells of the immune system, was thought to be helpful in treating chronic fatigue syndrome (ME/CFS).

Recently, Fluge and his colleagues published the results of the latest study of this drug in Annals of Internal Medicine. It marked the end of a nearly 15-year-long research story that began with great hope and enthusiasm, but ended in disappointment.

Now, the researchers have to look for other possibilities.

“You have to respect the results you get and adjust course,” says Fluge, who still believes it would be interesting to do more research on the immune system's role in ME/CFS.


Full article…



blog comments powered by Disqus
Previous Previous Page